The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, ...

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.